List of Excipients in Branded Drug HYRIMOZ

« Back to Dashboard

Hyrimoz Excipient Strategy and Commercial Opportunities in Adalimumab Biosimilars

Last updated: September 8, 2026

Hyrimoz is Sandoz’s adalimumab biosimilar, marketed in the United States as adalimumab-adaz. Its commercial positioning depends on three formulation decisions: citrate-free composition, high-concentration 100 mg/mL delivery, and ready-to-use autoinjector and prefilled-syringe presentations. These choices reduce injection volume, support patient preference, and create differentiation in a crowded post-Humira market.

The principal commercial opportunity is concentrated in the high-concentration, citrate-free product rather than in the underlying adalimumab molecule. Hyrimoz competes against Humira, Amjevita, Cyltezo, Hadlima, Abrilada, Idacio and other adalimumab biosimilars through device usability, pharmacy access, interchangeability, payer contracting and net price.

What is Hyrimoz and who markets it?

Hyrimoz is a biosimilar to AbbVie’s Humira, whose active ingredient is adalimumab, a tumor necrosis factor-alpha inhibitor. Sandoz markets Hyrimoz globally through local regulatory and commercial entities.

Attribute	Hyrimoz position
Active ingredient	Adalimumab-adaz
Reference product	Humira, adalimumab
Originator	AbbVie
Biosimilar sponsor	Sandoz
U.S. approval	October 2018
U.S. dosage forms	Prefilled syringe and autoinjector
U.S. concentration	50 mg/mL and 100 mg/mL presentations
U.S. high-concentration dose	40 mg/0.4 mL
U.S. interchangeability	FDA-approved interchangeable biosimilar status for the applicable Hyrimoz presentation
Administration	Subcutaneous injection
Major indications	Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and related inflammatory diseases
Regulatory reference	FDA prescribing information and Purple Book

The FDA approved Hyrimoz based on analytical, pharmacokinetic, immunogenicity and comparative clinical evidence establishing biosimilarity to Humira. Biosimilar approval does not require a separate clinical efficacy program for every approved Humira indication when the statutory requirements for extrapolation are met.[1]

What excipients are used in Hyrimoz?

Hyrimoz uses a relatively conventional protein-injection excipient system centered on mannitol and polysorbate 80. Water for injection is the vehicle. The exact inactive-ingredient profile varies by strength and jurisdiction.

U.S. Hyrimoz excipient profile

The U.S. prescribing information identifies the principal inactive ingredients as follows:

Presentation	Active concentration	Key excipient profile
40 mg/0.8 mL	50 mg/mL	Mannitol, polysorbate 80, sodium chloride and water for injection
40 mg/0.4 mL	100 mg/mL	Mannitol, polysorbate 80 and water for injection

Both presentations are citrate-free. The high-concentration formulation is also designed to reduce injection volume by 50% compared with the 50 mg/mL, 0.8 mL presentation.

The 100 mg/mL product has a strategic advantage because it supports delivery of the standard 40 mg dose in 0.4 mL. Lower injection volume can reduce injection time and may improve acceptance among patients receiving chronic self-injection. It also gives Sandoz a commercially meaningful product attribute without changing the active molecule.

Why are mannitol and polysorbate 80 important?

Mannitol is commonly used as a tonicity-adjusting and stabilizing excipient in parenteral protein formulations. In Hyrimoz, it supports an injectable formulation with acceptable osmolality and physical stability.

Polysorbate 80 is a nonionic surfactant used to limit protein adsorption to vial, syringe and device surfaces. It also helps reduce agitation-related aggregation during shipping, handling and administration. For monoclonal antibodies, surfactant selection and concentration affect particle formation, oxidation, degradation and container-closure compatibility.

The formulation must balance several competing requirements:

• Protein conformational stability
• Low visible and subvisible particle formation
• Compatibility with silicone-oil-coated syringes
• Compatibility with autoinjector components
• Acceptable injection pain
• Long-term refrigerated storage
• Tolerance of short-term temperature excursions
• Low immunogenicity risk
• Manufacturing consistency at commercial scale

The presence of polysorbate 80 creates its own control requirements because polysorbates can undergo hydrolysis and oxidation, generating degradants that may affect protein stability. A biosimilar manufacturer therefore needs a well-controlled excipient supply chain, validated analytical methods and defined limits for surfactant-related degradation products.

How does Hyrimoz’s citrate-free formulation create commercial value?

Citrate-free formulation is one of the strongest patient-facing differentiators in adalimumab. Citrate buffers were associated with injection-site discomfort in some Humira presentations. AbbVie subsequently introduced a citrate-free, lower-volume Humira formulation, which became the principal competitive benchmark for later biosimilars.

Hyrimoz’s citrate-free strategy provides four commercial benefits:

1. It avoids a formulation attribute that some patients associate with injection pain.
2. It allows Sandoz to compete against the current citrate-free Humira presentation rather than against an older formulation.
3. It supports conversion programs among patients already using self-injection.
4. It gives payers and specialty pharmacies a practical product distinction beyond price.

Citrate-free status does not independently establish clinical superiority. Its value is commercial and usability-related. Payers typically evaluate the product through net cost, formulary terms, interchangeability and supply reliability rather than through excipient composition alone.

What formulation patents protect Hyrimoz?

Hyrimoz is a biosimilar product and does not depend on an exclusive patent estate equivalent to Humira’s original product and formulation portfolio. Its commercial freedom depends on the expiration or settlement of AbbVie patent rights, the scope of Sandoz’s manufacturing and formulation claims, and regulatory rules governing biosimilar launch.

Humira patent protection and Hyrimoz launch

AbbVie held an extensive U.S. patent portfolio covering adalimumab formulations, dosing regimens, manufacturing processes and methods of treatment. The core U.S. composition-of-matter patent expired in 2016, while later patents delayed unrestricted biosimilar entry.

Sandoz reached a settlement with AbbVie permitting U.S. commercialization of Hyrimoz in 2023, before the full practical exhaustion of all asserted Humira-related rights. Sandoz launched Hyrimoz in the U.S. in 2023 under the settlement framework.[2]

The relevant legal question is not whether Hyrimoz has an independent “blocking” patent estate. The question is whether Sandoz’s product, manufacturing process and proposed uses fall within enforceable third-party claims. Settlement terms, patent licenses and covenants not to sue can be commercially more important than patents owned by the biosimilar sponsor.

Does Hyrimoz have Orange Book patents?

No conventional Orange Book listing should be expected for Hyrimoz because it is a biologic licensed under the Public Health Service Act. The FDA’s Purple Book is the principal reference for biologic approvals, biosimilar status and interchangeability. The Orange Book primarily covers approved small-molecule drug products under the Federal Food, Drug, and Cosmetic Act.[3]

Patent disputes involving Hyrimoz and Humira can still proceed in federal court under the Biologics Price Competition and Innovation Act. The absence of an Orange Book listing does not eliminate patent litigation risk.

When did Humira lose exclusivity, and when did Hyrimoz enter?

Humira’s 12-year U.S. reference-product exclusivity period ended in December 2022. Commercial biosimilar entry began in 2023 under individual settlements between AbbVie and biosimilar sponsors.

Event	Date or period
Humira FDA approval	2002
Humira U.S. biologic exclusivity	Ended in December 2022
Hyrimoz FDA approval	October 2018
Hyrimoz U.S. commercial launch	2023
Major U.S. adalimumab biosimilar entry wave	2023-2024
Continuing market issue	Formulary access and net price competition

Hyrimoz’s early approval did not provide immediate U.S. commercial access. Patent settlements controlled the timing of launch.

Is Hyrimoz interchangeable with Humira?

The FDA granted Hyrimoz interchangeable biosimilar status for the applicable U.S. product presentation. Interchangeability can permit pharmacy-level substitution under state law without prescriber intervention, subject to state-specific substitution rules.

Interchangeability has commercial value because it can:

• Improve pharmacy substitution potential
• Reduce administrative friction
• Support preferred formulary placement
• Increase dispensing through specialty-pharmacy channels
• Strengthen employer and payer conversion programs

Interchangeability is not the same as automatic substitution in every state. State pharmacy laws, payer protocols, prescriber instructions and specialty-pharmacy practices continue to control actual switching behavior.

How strong is the Hyrimoz formulation strategy?

The formulation strategy is commercially strong but technically imitable. Citrate-free, high-concentration adalimumab is now a market expectation rather than a unique barrier.

Strengths

Formulation or product attribute	Commercial effect
Citrate-free composition	Supports patient comfort positioning
100 mg/mL concentration	Reduces 40 mg dose volume to 0.4 mL
Autoinjector	Supports home administration and adherence
Prefilled syringe	Serves patients who prefer dose visibility or manual control
Mannitol and polysorbate 80 system	Uses familiar parenteral protein formulation excipients
Interchangeable status	Expands substitution and payer utility
Multiple presentations	Supports segmentation by patient preference

Limitations

The excipient system alone creates limited defensibility. Competitors can also use citrate-free formulations, high concentration, polysorbate-based stabilization and similar devices. Hyrimoz’s defensibility therefore depends more heavily on:

• FDA interchangeability
• Device reliability
• Injection-force performance
• Specialty-pharmacy distribution
• Payer contracting
• Supply continuity
• Patient-support services
• Manufacturing scale
• Global regulatory approvals

The strongest technical barrier is usually not the named excipient. It is the integrated product system covering protein quality, aggregation control, device compatibility, container closure, process yield and validated shelf life.

What manufacturing and intellectual-property barriers affect Hyrimoz?

Adalimumab manufacturing requires control of mammalian-cell culture, purification, viral clearance, aseptic filling and cold-chain logistics. The formulation is only one part of the cost and risk structure.

Key manufacturing barriers include:

• Consistent glycosylation and charge-variant profiles
• Low aggregate and fragment levels
• Control of host-cell proteins and residual DNA
• Polysorbate degradation monitoring
• Low particle burden after filling
• Compatibility with prefilled syringes and autoinjectors
• Stable refrigerated shelf life
• Commercial-scale batch reproducibility

The biosimilar must remain highly similar to Humira while meeting its own release specifications. Manufacturing changes after approval may require comparability studies and regulatory notification or approval.

The principal IP risks involve process patents, formulation claims, dosing regimens, device claims and method-of-treatment patents. Sandoz’s U.S. settlement with AbbVie reduced launch risk, but it did not make every possible patent theory irrelevant. Patent risk can re-emerge if a later product change, new indication, device configuration or manufacturing process creates a distinct infringement issue.

Which companies challenge Hyrimoz in the adalimumab market?

Hyrimoz competes with a large group of Humira biosimilars and authorized or branded alternatives.

Competitor	Sponsor or manufacturer	Key commercial attribute
Humira	AbbVie	Reference product; citrate-free high-concentration benchmark
Amjevita	Amgen	Early U.S. adalimumab biosimilar entrant
Cyltezo	Boehringer Ingelheim	FDA interchangeable biosimilar
Hadlima	Samsung Bioepis and Organon	High-concentration and citrate-free presentations
Abrilada	Pfizer	U.S. adalimumab biosimilar
Idacio	Fresenius Kabi	International biosimilar competitor
Yuflyma	Celltrion	High-concentration, citrate-free positioning in several markets
Hyrimoz	Sandoz	Interchangeable, citrate-free and high-concentration U.S. positioning

Commercial competition is likely to separate into two segments. One segment emphasizes the lowest net price and payer savings. The other emphasizes interchangeable status, high concentration, device usability and dependable specialty-pharmacy service.

What are the commercial opportunities for Hyrimoz excipients?

High-concentration self-injection

The 100 mg/mL formulation supports lower injection volume and is the most direct commercial opportunity. It can help retain patients who might otherwise switch from a biosimilar to another product based on injection burden.

Device and formulation combinations

The most valuable opportunity is an integrated combination of:

• Citrate-free formulation
• Low injection volume
• Low injection force
• Short injection time
• Ergonomic autoinjector
• Clear dose confirmation
• Low residual volume

These attributes can support a differentiated device patent or design-right strategy even when the excipient composition is conventional.

Lifecycle management

Potential lifecycle strategies include:

• New autoinjector geometry
• Pediatric-friendly device configuration
• Increased shelf life
• Improved temperature-excursion tolerance
• Alternate syringe materials
• Silicone-oil reduction
• New packaging for home delivery
• Regional presentations aligned with local substitution rules

Each change requires regulatory assessment. A new excipient, concentration or device can create comparability obligations and may alter the biosimilar’s regulatory status.

Contract manufacturing and licensing

Sandoz can create value through manufacturing partnerships involving:

• Drug substance capacity
• Fill-finish capacity
• Autoinjector assembly
• Regional packaging
• Specialty-pharmacy distribution
• Cold-chain logistics

For potential licensors, the strongest assets are likely to be device technology, low-particle formulations, surfactant-stability systems, container-closure technology and scalable fill-finish processes. A generic mannitol-polysorbate formulation has low standalone licensing value unless protected by process performance, stability data or device integration.

What is the revenue exposure and generic launch risk?

Hyrimoz operates in a high-revenue biologic category but faces rapid price erosion. The relevant commercial exposure is not only the product’s gross sales. It includes Sandoz’s broader immunology portfolio, specialty-pharmacy relationships and biosimilar contracting platform.

Generic-style substitution risk is lower in operational complexity than for small molecules but higher in commercial price pressure. Adalimumab biosimilars require biologic manufacturing, cold-chain distribution and payer conversion. Entry can be rapid after launch, while market share can vary sharply by channel.

Risk factor	Effect on Hyrimoz
Multiple adalimumab biosimilars	Reduces pricing power
Payer-preferred competitors	Can restrict access
Humira rebates and formulary defense	May slow conversion
Interchangeability	Improves substitution potential
High-concentration presentations	Reduces differentiation gap between products
Supply interruptions	Can create rapid share loss
State substitution rules	Produce uneven U.S. uptake
Physician inertia	Slows switching in stable patients
Specialty-pharmacy control	Increases importance of contracting

Hyrimoz’s revenue potential is strongest where Sandoz combines competitive net pricing with preferred access and reliable supply. The high-concentration, citrate-free presentation is more likely to protect volume than to sustain a large premium.

What is the regulatory status of Hyrimoz?

Hyrimoz is FDA-approved as a biosimilar to Humira and is listed in the FDA Purple Book. It is also authorized in Europe and other jurisdictions under local biosimilar frameworks. Product names, concentrations, device presentations and substitution rules vary by country.

In the U.S., regulatory value comes from:

• Biosimilar approval
• Extrapolated indications
• Interchangeable status for the applicable product
• Multiple self-injection devices
• FDA-approved high-concentration formulation

In Europe, pharmacy-level substitution is governed by national policy rather than by a single EU-wide automatic-substitution rule. Commercial access therefore depends heavily on national tendering, hospital procurement and reimbursement decisions.

Key Takeaways

• Hyrimoz’s core excipient system uses mannitol, polysorbate 80 and water for injection, with sodium chloride included in the 50 mg/mL presentation.
• The product is citrate-free and available in a 100 mg/mL, 40 mg/0.4 mL high-concentration presentation.
• The strongest commercial benefit is lower injection volume combined with an autoinjector or prefilled syringe.
• Excipient composition alone provides limited patent strength because competitors can use similar stabilizer systems.
• The more defensible asset is the integrated formulation-device-manufacturing package.
• Hyrimoz’s U.S. interchangeability status improves substitution and payer positioning.
• U.S. launch timing was controlled by AbbVie patent settlements rather than by the 2018 biosimilar approval date.
• Hyrimoz is tracked through the FDA Purple Book, not through conventional Orange Book listings.
• The principal commercial risks are payer competition, Humira rebate defense, multiple biosimilar entrants and rapid net-price erosion.
• The most attractive lifecycle opportunities involve device usability, low injection force, stability, packaging and manufacturing efficiency.

FAQs About Hyrimoz Excipients and Commercial Strategy

Does Hyrimoz contain citrate?

No. Hyrimoz is marketed as a citrate-free adalimumab formulation in its principal U.S. presentations.

Is Hyrimoz the same concentration as Humira?

Hyrimoz is available at 100 mg/mL, matching the high-concentration format used by current Humira presentations. It is also available in a 50 mg/mL presentation in the United States.

Can Hyrimoz be substituted automatically for Humira?

Substitution depends on the FDA interchangeability designation, the dispensed presentation and applicable state pharmacy law. Interchangeability does not create identical substitution rules in every jurisdiction.

Do Hyrimoz excipients create an allergy risk?

Patients can react to active or inactive ingredients, but excipient-related risk must be evaluated against the product label and the patient’s clinical history. Mannitol and polysorbate 80 are established pharmaceutical excipients.

Can a competitor patent a better adalimumab excipient formulation?

Potentially, if the formulation satisfies patentability requirements and is novel, nonobvious and adequately described. Commercial protection is stronger when the formulation is linked to measurable stability, device performance, manufacturing yield or clinical-use benefits.

References

1. U.S. Food and Drug Administration. (2023). Hyrimoz (adalimumab-adaz) prescribing information.
2. Sandoz. (2023). Sandoz launches Hyrimoz, an interchangeable biosimilar to Humira, in the United States.
3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
4. European Medicines Agency. (2018). Hyrimoz: EPAR product information.
5. U.S. Food and Drug Administration. (2023). Biosimilar and interchangeable biosimilar biological products.